Summarized & reviewed by The Peptide Dispatch Editorial Team · Last reviewed September 21, 2026
A standard lipid panel reports four numbers: total cholesterol, HDL cholesterol, LDL cholesterol, and triglycerides. A fifth number can be obtained from three of those four using nothing but subtraction. It requires no additional blood, no additional cost, and no additional visit. It is not printed on any routine report in the United States, it is not in the summary your portal shows you, and…
This dispatch covers Your Lipid Panel Already Contains a Number That Beats LDL on Causal Risk. No Laboratory Prints It. in the research research category, authored by The Peptide Dispatch Editorial Team. Estimated reading time: 10 minutes. The Peptide Dispatch curates peer-reviewed peptide research for self-directed learners. All summaries are presented for Research Use Only and do not constitute medical advice.
A standard lipid panel reports four numbers: total cholesterol, HDL cholesterol, LDL cholesterol, and triglycerides. A fifth number can be obtained from three of those four using nothing but subtraction. It requires no additional blood, no additional cost, and no additional visit. It is not printed on any routine report in the United States, it is not in the summary your portal shows you, and most people reading their own results have never heard its name.
The number is remnant cholesterol, and the arithmetic is this:
Remnant cholesterol = total cholesterol minus HDL cholesterol minus LDL cholesterol
That is the whole calculation. If your total cholesterol is 210, your HDL is 45, and your LDL is 130, your remnant cholesterol is 35 mg/dL. You can do this for the panel you already have, from a result drawn years ago, on a phone calculator.
The reason this matters is not that remnant cholesterol is an interesting secondary marker. It is that in the largest human genetic studies conducted on the question, remnant cholesterol carried a higher causal risk for ischemic heart disease than LDL did, measured in the same population, in the same analysis, by the same method.
LDL is one class of cholesterol-carrying particle. It is not the only one. Triglyceride-rich lipoproteins, meaning VLDL produced by the liver and chylomicrons produced by the gut, also carry cholesterol. As those particles are processed in circulation and shed triglyceride, what is left behind is a smaller, denser, cholesterol-enriched particle called a remnant.
Remnant cholesterol is the cholesterol carried inside all of those triglyceride-rich particles and their remnants. Total cholesterol counts every cholesterol-carrying particle in the sample. Subtract the cholesterol in HDL and the cholesterol in LDL, and what remains is, by definition, the cholesterol riding in the triglyceride-rich fraction.
Two features of these particles make them relevant to an artery. They are small enough to cross the endothelial layer and become trapped in the arterial wall, and each particle carries considerably more cholesterol than an LDL particle does. Unlike LDL, they do not appear to require oxidative modification before macrophages take them up and become foam cells.
This is also why the marker is not redundant with triglycerides. Triglycerides measure the fat content of those particles. Remnant cholesterol measures the cholesterol content, which is the part that ends up in the plaque.
Observational studies showing that a marker tracks with disease are cheap and common. They do not establish that the marker causes anything. Mendelian randomization is the design that addresses this: it uses inherited genetic variants that raise or lower a marker from birth, which are allocated essentially at random at conception and are not subject to the reverse causation and lifestyle confounding that wreck observational lipid research.
In 2013, Varbo and colleagues published such an analysis in the Journal of the American College of Cardiology. They genotyped 73,513 people from Copenhagen, of whom 11,984 had ischemic heart disease diagnosed between 1976 and 2010, and selected fifteen genetic variants affecting remnant cholesterol, HDL, or LDL.
The results, per 1 mmol/L (39 mg/dL) genetically determined increase:
| Lipid fraction | Causal odds ratio (95% CI) | Observational |
|---|---|---|
| Remnant cholesterol | 2.8 (1.9 to 4.2) | 1.4 |
| LDL cholesterol | 1.5 (1.3 to 1.6) | 1.1 |
| HDL cholesterol (per 1 mmol/L decrease) | 0.7 (0.4 to 1.4) | 1.6 |
Read the three rows against each other, because the contrast is the point. LDL came out causal, as expected, which validates the method. HDL came out with a confidence interval spanning 1.0, meaning no causal signal at all, despite a strong observational association. And remnant cholesterol came out with roughly twice the causal effect size of LDL.
A second analysis from the same group, published in Circulation that year, extended this to 60,608 individuals across three Copenhagen cohorts. A 1 mmol/L higher remnant cholesterol was causally associated with a 28 percent higher C-reactive protein (95% CI 10 to 48). For LDL, there was no causal association with CRP whatsoever. The causal risk ratio for ischemic heart disease in that analysis was 3.3 for remnant cholesterol against 1.8 for LDL. The authors noted the remnant cholesterol associations held in people without diabetes and without obesity.
That finding has a mechanistic implication worth sitting with. Elevated remnant cholesterol appears to cause both the plaque and the low-grade inflammation. Elevated LDL causes the plaque without the inflammation. If you have been told your cholesterol is fine and your CRP is mildly elevated with no obvious explanation, these are the particles that connect the two.
A review by Parhofer, Chapman, and Nordestgaard summarizing this body of work put the risk gradient in concrete terms. Comparing people with remnant cholesterol above 2.3 mmol/L (89 mg/dL) against those below 0.5 mmol/L (19 mg/dL), risk was approximately:
| Outcome | Elevated risk |
|---|---|
| Aortic stenosis | 1.5-fold |
| All-cause mortality | 2-fold |
| Ischemic stroke | 3-fold |
| Myocardial infarction | 5-fold |
| Acute pancreatitis | 10-fold |
All-cause mortality, not just cardiac mortality. A doubling.
For a rough orientation on your own result: values under about 20 mg/dL sit in the low band used in that comparison, values around 30 mg/dL are common and unremarkable in Western populations, and values above 40 mg/dL represent meaningful elevation, with the highest-risk band in the studies above starting near 89 mg/dL. These are population reference points from research cohorts, not a clinical cutoff, and no consensus threshold has been established.
Remnant cholesterol rises with insulin resistance, visceral adiposity, and high carbohydrate or alcohol intake. It is one of the lipid abnormalities that appears early in metabolic dysfunction, often while LDL still looks unremarkable.
A 2015 analysis in Circulation Research followed roughly 90,000 Copenhagen participants and asked what mediates the increased heart disease risk that comes with obesity. Remnant cholesterol accounted for 7 percent of the excess risk in the genetic analysis and 20 percent observationally, putting it alongside LDL and systolic blood pressure as one of the three main mediators. The authors' conclusion was that lowering these markers may benefit people who are not able to achieve sustained weight loss.
In type 2 diabetes, where residual cardiovascular risk persists even after LDL is driven down, reviews of the evidence place elevated remnant cholesterol among the likeliest explanations. A 2025 piece in the European Heart Journal framed residual risk beyond LDL as resting on three pillars: inflammation, remnant cholesterol, and lipoprotein(a).
This is the practical argument for calculating it. The person whose LDL is 105 and whose triglycerides are 180 and who has been told the panel is unremarkable may have a remnant cholesterol near 40, which is the finding that explains why the rest of the picture does not fit.
Three limits deserve to be stated plainly, because the enthusiasm around this marker regularly outruns them.
First, the calculated value is an estimate, not a direct measurement. It inherits the error of the LDL value it is built from. When triglycerides run high, the Friedewald equation many laboratories still use to estimate LDL becomes unreliable, which distorts the subtraction in ways that are not always conservative. A directly measured or newer-equation LDL makes the calculation more trustworthy.
Second, and more important: no large trial has yet shown that lowering remnant cholesterol specifically, as a primary objective, reduces cardiovascular events. The drug trials that lowered it as a side effect have been ambiguous. Fibrates and lower-dose omega-3 preparations lowered remnant cholesterol without delivering clear event reduction on top of statins, and the most plausible explanation is that they did not reduce the total number of apoB-containing particles. Causal biology does not automatically translate into a successful drug.
Third, that ambiguity cuts a specific way. The current reading of the evidence is that a remnant-lowering strategy matters to the extent that it also lowers apoB, the count of atherogenic particles. Remnant cholesterol is best understood as a marker that tells you where your risk is coming from, not as a target to be chased in isolation.
What it is unambiguously good for is detection, and detection is free. The drivers that raise it, insulin resistance, visceral fat, alcohol, and refined carbohydrate load, are also the drivers most responsive to changes that require no prescription at all.
Take your most recent lipid panel. Subtract HDL and LDL from total cholesterol. Fasting status does not invalidate this; the Copenhagen work that produced every number above used nonfasting samples deliberately, on the grounds that nonfasting blood is the state a human spends most of the day in.
Then compare the answer against the rest of the picture. A remnant cholesterol under 20 with a normal LDL is a genuinely reassuring pair. A remnant cholesterol above 40, particularly alongside a waist measurement that has been climbing, a fasting insulin nobody ordered, or a CRP that has been dismissed as nonspecific, is a coherent signal rather than three unrelated oddities.
Nothing in this requires a new test. The number has been sitting in every lipid panel ever drawn. It is not printed because the report format predates the evidence, and the evidence, at this point, runs to hundreds of thousands of genotyped people.
Based on articles retrieved from PubMed:
Educational content only. This article describes published research and laboratory interpretation. It is not medical advice and does not recommend any test, supplement, or treatment for any individual. Discuss your own results with a qualified clinician.
Educational content — not medical advice. Effects described are drawn from cited research in study subjects.